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Background
Juvenile idiopathic arthritis (JIA) designates a group of inflammatory joint diseases of unknown aetiology with onset before the age of 16 (1) . The disease course is usually self-limiting although a substantial proportion has chronic progressive disease. Considerable efforts have been made to enable prospective structured assessments of disease activity, course and outcome of JIA (2) .
However, there is still a need to identify early predictors of aggressive disease leading to joint destruction.
'Cartilage oligomeric matrix protein' (COMP) is mainly located in hyaline cartilage, but also in tendons, skin, and synovial fibroblasts (3) (4) (5) . Growth hormone (GH) and insulin-like growth factor type-1 (IGF-I) up-regulate COMP in cultured human chondrocytes. Serum COMP (sCOMP) increases upon paediatric GH therapy (6) . Hepatic IGF-1 production increases as a response to pituitary-gland GH release, which stimulates bone growth and induces COMP gene expression (6) .
In early adult rheumatoid arthritis (RA), elevated/rising sCOMP has been reported to predict erosive disease (7) . Decreased sCOMP upon treatment with corticosteroids and/or tumour necrosis factor inhibitors has been interpreted as a sign of cartilage protection (8) . However, Turesson et al reported raised sCOMP in pre-RA subjects testing negative for anti-citrullinated peptide antibodies, i.e. a risk marker of erosive disease (9).
This study was done to investigate sCOMP, IGF-1 and C-reactive protein (CRP) levels in prevalent JIA
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METHODS
Subjects
JIA group: 52 children diagnosed with JIA were recruited, and categorised according to the ILAR classification criteria (1) . Enrolment was done at planned visits to a paediatrician (PL) at Vrinnevi hospital, Norrköping, Sweden. Estimation of disease activity was based on presence of ≥1 palpable synovitis and/or motion-induced joint pain. By this definition, 69 % had active disease.
29% had x-ray proven erosions. Patient characteristics and on-going medications are summarized in Table 1 . 'IgE-referents': 120 children testing negative for IgE-antibodies against a panel of common allergens (60 girls/60 boys aged 1.5-17.8 years, mean 9.2/median 9.5).
Serum analyses
Enzyme-linked immunosorbent assays were used to analyse sCOMP (COMP 
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RESULTS
Average sCOMP was slightly lower in JIA than in IgE-referents (p<0.05) (Figure 1 ), but higher Clinically active/inactive JIA patients did not differ regarding sCOMP levels.
Although not reaching statistical significance, a tendency to higher average CRP was recorded among the 36 clinically active compared to 16 clinically inactive JIA-patients (p=0.053).
Average CRP was higher among infected children compared both to IgE-referents (p<0.0001) and JIA (p<0.0001).
Among IgE-referents there was a significant correlation between raised CRP and decreased sCOMP (rho -0.27;p<0.005), but not among infected children (rho -0.12;p=0.4) nor in JIA (Rho -0.023;p=0.87). CRP in JIA and IgE-referents differed significantly.
Regarding IGF-1, a low negative correlation was registered vis-à-vis CRP (rho = -0.25, p <0.01).
IGF-1 levels correlated similarly with age (rho= 0.72, p<0.01) in all three populations, whereas no correlations were registered when comparing sCOMP and IGF-1 (rho=0.08, p=0.22). IGF-1 was significantly lower among infected children (mean 6.6 µg/l), compared both to IgE-referents (mean 13.6 µg/l, p<0.001) and JIA (mean 12.6 µg/l, p<0.001) after correction for age. Compared to IgE-referents, COMP:IGF-1 ratio was significantly lower in JIA as well as in infected children, even when corrected for age.
DISCUSSION
This study was undertaken to analyse sCOMP levels in JIA patients compared to children/adolescents hospitalised due to on-going infection, and children seronegative regarding IgE-mediated allergy. The few published studies on sCOMP in JIA, have all concluded that sCOMP is reduced during active inflammatory disease (10, 11) , and that it is related to growth retardation (6, 11) . Although confirming a tendency to lowered sCOMP in JIA-patients with raised CRP (p=0.053), this was not seen comparing patients classified clinically active/inactive.
Discrepancies between different studies may depend on differences in patient materials, reference populations, disease duration, medication, etc.
Our study revealed that cases with infectious disease had markedly lower sCOMP compared to 'IgE-referents'. JIA-patients also had slightly (but statistically significant) lower sCOMP levels than the 'IgE-referents, but distinctly higher levels compared to the infection group. By dividing our JIA cases into a 'low-age group' (0-15 years) and a higher-aged group (16-18 years) we confirmed lower sCOMP among the older (presumably pubertised) adolescents compared to the lower-aged growing children.
Like all measurements of circulating biomarkers, interpretation of raised or lowered levels of sCOMP is intricate. Thus, results of serum measurements include aspects on rates of synthesis and degradation, as well as rates of uptake into and clearance from the circulation. Serum concentrations can also be affected by the nature and fate of the circulating analyte, which raises a number of questions, e.g.:
-do reported sCOMP levels reflect native protein and/or degradation fragments?
-can interaction between sCOMP and other circulating proteins (auto-antibodies?) or cells affect the results?
-is the elimination rate of sCOMP and COMP fragments affected by deficient organ function (liver; spleen; kidney)?
-do capture antibodies of the ELISA kit and/or circulating rheumatoid factor interfere with the test results?
Raised levels of sCOMP may thus be explained by increased synthesis e.g. during growth in infancy/adolescence or depending on tissue repair, but could also reflect on-going bone and cartilage destruction during local or systemic inflammation. Different sCOMP fragments may reflect different aspects on synthesis, degradation, elimination rates, etc. Overall, raised sCOMP levels can be induced by growth hormone, which is a likely explanation to elevated sCOMP recorded in children/adolescents during periods of high growth velocity (6) . This may well explain the differences regarding positive COMP:CRP correlations reported in adult RA and the opposite in children with systemic inflammation, regardless of underlying cause. Tocilizumab therapy, which is efficiently CRP-lowering, has been shown to raise COMP levels to normal in young persons with JIA (12). Whether or not COMP interacts with CRP is unknown, but both of these molecules bind complement protein C1q, resulting in COMP-mediated inhibition of classical complement activation (13) and CRP-mediated activation of the classical pathway (14) . Regarding the effects of GH, it is likely that lowered COMP in JIA relates to growth retardation in patients with on-going inflammation. GH induces IGF-1, which has been reported to be lowered in JIA (15) and, intriguingly, COMP gene expression is up-regulated by IGF-1 (16) . Further, it is known 8 that sCOMP levels rise in children treated with growth hormone (6) . Contrary to the predictive value of sCOMP in early RA with regard to erosive disease (4), Gilliam et al found that sCOMP in JIA patients who did not develop joint erosions and joint space narrowing were higher compared to patients with progressive joint damage (17) . In our study, the average sCOMP level was slightly higher in the IgE-negative reference group compared to the JIA-group, which in turn had significantly higher COMP levels compared to children with on-going infection.
The results of this study confirm that clinical and biological correlates of sCOMP differ between children/adolescents and adults, and indicate that sCOMP is of limited clinical value as a biomarker in JIA.
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